ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ertugliflozin

Also written as “Ertugliflozin 5 mg”, “Ertugliflozin” and “Ertugliflozin 15 mg”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Fatty Liver · Renal Insufficiency, led by 3 companies.

Drug pageErtugliflozin: every studyAll 37 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 7, 201322 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck200 open or runningphase 3since Oct 7, 2013Oct 1, 2009none ahead
Getz Pharmaits history only11 open or runningphase 4since Nov 18, 2022Nov 18, 2022none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 3, 2025Dec 3, 2025none ahead

Also a collaborator on its studies: Pfizer.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Merck only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Oct 1, 2009.

  1. Jan 29, 2010Phase 2 study in Diabetes Mellitus, Type 2NCT01059825 · 375 enrolled
  2. Mar 26, 2010Phase 2 study in Diabetes Mellitus, Type 2NCT01096667 · 194 enrolled
  3. Apr 27, 2010Phase 1 study in HealthyNCT01114568 · 12 enrolled
  4. May 19, 2010Phase 1 study in Diabetes Mellitus, Type 2NCT01127308 · 6 enrolled
  5. Oct 13, 2010Phase 1 study in Diabetes Mellitus, Type 2NCT01223339 · 24 enrolled
  6. Sep 20, 2013Phase 1 study in Renal InsufficiencyNCT01948986 · 36 enrolled
  7. Oct 7, 2013Phase 3 study in Diabetes Mellitus, Type 2NCT01958671 · 461 enrolled
  8. Nov 12, 20133 phase 3 studies in Diabetes Mellitus, Type 2NCT01986881, NCT01986855, NCT01999218
  9. Jan 9, 20142 phase 3 studies in Diabetes Mellitus, Type 2NCT02033889, NCT02036515
  10. Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02099110 · 1,233 enrolled
  11. Apr 14, 2014Phase 1 study in Diabetes Mellitus, Type 2NCT02115347 · 16 enrolled
  12. Aug 25, 2014Phase 3 study in Diabetes Mellitus, Type 2NCT02226003 · 291 enrolled
  13. Dec 11, 2015Phase 3 study in Diabetes Mellitus, Type 2NCT02630706 · 506 enrolled
  14. Jul 11, 2019Phase 3 study in Diabetes Mellitus, Type 2NCT04029480 · 166 enrolled · United States, Belgium, Canada and more

TargetBeta

SLC5A2 →read by rule
“Sodium/glucose cotransporter 2 inhibitor; Sodium/glucose cotransporter 2 inhibitor”ChEMBL 37, by rule

Other programs on SLC5A2

ProgramCompanyFurthest phaseStudies
empagliflozinruleBoehringer Ingelheimphase 4142
dapagliflozinAstraZenecaphase 4133
vicadrostatBoehringer Ingelheimphase 316
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12

Studies

All 20 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT04029480Diabetes Mellitus, Type 2 · United States, Belgium, Canada and more3CompletedApr 11, 2025166
NCT02630706Diabetes Mellitus, Type 23CompletedDec 27, 2017506
NCT02226003Diabetes Mellitus, Type 23CompletedFeb 23, 2016291
NCT02115347Diabetes Mellitus, Type 21CompletedJan 10, 201516
NCT02099110Diabetes Mellitus, Type 23CompletedMay 26, 20161,233
NCT02036515Diabetes Mellitus, Type 23CompletedJun 6, 2016464
NCT02033889Diabetes Mellitus, Type 23CompletedAug 3, 2017621
NCT01999218Diabetes Mellitus, Type 23CompletedApr 18, 20171,326
NCT01986881Diabetes Mellitus, Type 23CompletedDec 27, 20198,246
NCT01986855Diabetes Mellitus, Type 23CompletedSep 28, 2016468
NCT01958671Diabetes Mellitus, Type 23CompletedJul 28, 2016461
NCT01948986Renal Insufficiency1CompletedOct 6, 201436
NCT01223339Diabetes Mellitus, Type 21CompletedFeb 201124
NCT01127308Diabetes Mellitus, Type 21CompletedJul 20106
NCT01114568Healthy1CompletedJun 201012
NCT01096667Diabetes Mellitus, Type 22CompletedFeb 9, 2011194
NCT01059825Diabetes Mellitus, Type 22CompletedJan 20, 2011375
NCT01054300Diabetes Mellitus, Type 21CompletedApr 7, 201052
NCT01018823Healthy Volunteer1CompletedMar 18, 201040
NCT00989079Diabetes Mellitus, Type 21CompletedDec 11, 200924

How it is read

Names in the registry

  • “Ertugliflozin 5 mg”, 10 entries
  • “Ertugliflozin”, 8 entries
  • “Ertugliflozin 15 mg”, 5 entries
  • “Ertugliflozin 10 mg”, 4 entries
  • “Ertugliflozin 1 mg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.